Trial Profile
To evaluate and characterize a single weight-based dose of rasburicase followed by oral allopurinol for treatment of tumor lysis syndrome as well as to determine the effect on serum creatinine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Rasburicase (Primary) ; Allopurinol
- Indications Tumour lysis syndrome
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association